Search results for " aggregation"

showing 10 items of 441 documents

Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2.

2016

The symbiotic gut microbiota play pivotal roles in host physiology and the development of cardiovascular diseases, but the microbiota-triggered pattern recognition signaling mechanisms that impact thrombosis are poorly defined. In this article, we show that germ-free (GF) and Toll-like receptor-2 (Tlr2)-deficient mice have reduced thrombus growth after carotid artery injury relative to conventionally raised controls. GF Tlr2-/- and wild-type (WT) mice were indistinguishable, but colonization with microbiota restored a significant difference in thrombus growth between the genotypes. We identify reduced plasma levels of von Willebrand factor (VWF) and reduced VWF synthesis, specifically in he…

0301 basic medicineBlood Plateletsmedicine.medical_specialtyEndotheliumPlatelet AggregationImmunologyBiologyBiochemistry03 medical and health sciencesMiceVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineAnimalsGerm-Free LifePlateletThrombusIntegrin bindingMice KnockoutToll-like receptorThrombosisCell BiologyHematologymedicine.diseaseToll-Like Receptor 2Gastrointestinal MicrobiomeTLR2030104 developmental biologymedicine.anatomical_structureEndocrinologyLivercardiovascular systembiology.proteinSignal transductioncirculatory and respiratory physiologySignal TransductionBlood
researchProduct

Using Induced Ordered Weighted Averaging (IOWA) Operators for Aggregation in Cross-Efficiency Evaluations

2014

This paper proposes an enhancement of the cross-efficiency evaluation through the aggregation of cross-efficiencies by using a particular type of induced ordered weighted averaging IOWA operator. The use of a weighted average of cross-efficiencies for the calculation of the cross-efficiency scores, instead of the usual arithmetic mean, allows us to introduce some flexibility into the analysis. In particular, the main purpose of the approach we present is to provide aggregation weights that reflect the decision maker DM preferences regarding the relative importance that should be attached to the cross-efficiencies provided by the different decision-making units. To do it, an ordering is to b…

business.industryType (model theory)Theoretical Computer ScienceHuman-Computer InteractionVariable (computer science)Matrix (mathematics)Operator (computer programming)Artificial IntelligenceArtificial intelligencebusinessOrdered weighted averaging aggregation operatorWeighted arithmetic meanAlgorithmRowSoftwareMathematicsArithmetic meanInternational Journal of Intelligent Systems
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct

Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease

1986

The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II-III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg X min for 4 h, with an interval of 2-3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation a…

AdultMaleTime FactorsPlatelet AggregationDiastoleHemodynamicsArterial Occlusive DiseasesPlaceboRandom AllocationDrug DiscoveryHeart ratemedicineHumansPlateletIloprostGenetics (clinical)AgedDose-Response Relationship Drugbusiness.industryHemodynamicsCardiovascular AgentsGeneral MedicineMiddle AgedEpoprostenolBlood pressureAnesthesiaCardiovascular agentDrug EvaluationMolecular MedicineFemalelipids (amino acids peptides and proteins)businesscirculatory and respiratory physiologyIloprostmedicine.drugKlinische Wochenschrift
researchProduct

Platelet aggregation, ATP release and cytoplasmic Ca2+ movement: the effects of cloricromene.

1994

A placebo-controlled, double-blind, randomized, cross-over study was performed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other volunteers received identical placebo capsules. Subsequently, after a 7-day wash-out period, at day 15, each subject received the other treatment. Blood samples were taken on days 1 and 15 (1st day of each treatment) as well as on days 7 and 21 (7th day of each treatment) before the morning drug administration and 2 and 4 hours later. Platelet aggregation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin…

AdultMaleCytoplasmAdolescentPlatelet Aggregationchemistry.chemical_elementAdministration OralPharmacologyCalciumPlaceboAdenosine TriphosphateDouble-Blind MethodOral administrationHumansPlateletSecretionWhole bloodCalcium metabolismCross-Over StudiesChemistryChromonarHematologyMiddle AgedCrossover studyAdenosine DiphosphateAnesthesiaCalciumFemaleCollagenPlatelet Aggregation InhibitorsThrombosis research
researchProduct

GAS6

2017

Venous thrombosis is determined by the recruitment of monocytes and neutrophils to the inflamed endothelium and is primarily influenced by the plasmatic coagulation system.1 Monocyte tissue factor (TF) was identified as the causative trigger for intraluminal fibrin formation and thrombus load in the inferior vena cava (IVC) stenosis model, resembling human deep vein thrombosis.1 Although monocyte TF is prothrombotic, the TF expressed by activated endothelial cells triggers proinflammatory protease-activated receptor signaling pathways.2,3 See accompanying article on page 1315 In the past years, GAS6 (growth arrest–specific gene-6) was described as a major regulatory protein of prothrombotic…

0301 basic medicineEndotheliumVena Cava Inferior030204 cardiovascular system & hematologyFibrinogenInferior vena cavaMonocytes03 medical and health sciencesTissue factor0302 clinical medicinemedicineHumansPlateletThrombusVenous ThrombosisGAS6business.industryImpaired platelet aggregationmedicine.disease030104 developmental biologymedicine.anatomical_structuremedicine.veinAnesthesiaCancer researchCardiology and Cardiovascular MedicinebusinessGasolinemedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

PHOSPHODIESTERASE INHIBITORS PIROXIMONE AND ENOXIMONE INHIBIT PLATELET AGGREGATION IN VIVO AND IN VITRO

1997

The phosphodiesterase type III inhibitors piroximone (PIR) and enoximone (ENO) exert positive inotropic and vasodilating effects in patients with severe heart failure. PIR and ENO raise cyclic AMP levels in cardiac and vascular smooth muscle cells. Platelet activity is also regulated by intracellular levels of cyclic AMP. In this study we have investigated the effects of PIR and ENO on platelet activity in vivo and in vitro. PIR and ENO inhibited ADP induced platelet aggregation in a time- and concentration-dependent manner with IC50-values of 67 +/- 14 mumol/l and 129 +/- 6 mumol/l, respectively. Coincubation of PIR with the adenylate cyclase activator iloprost resulted in a synergistic po…

Blood PlateletsMalemedicine.medical_specialtyCardiotonic AgentsVascular smooth musclePlatelet AggregationPhosphodiesterase InhibitorsVasodilationIn vivoInternal medicineCyclic AMPmedicineAnimalsHumansEnoximonePlateletPlatelet activationRats WistarEnoximonebiologyChemistryImidazolesPhosphodiesteraseHematologyRatsEndocrinologyEnzyme inhibitorbiology.proteinCalciumPlatelet Aggregation Inhibitorsmedicine.drugThrombosis Research
researchProduct

Blood rheology at term in normal pregnancy and in patients with adverse outcome events.

2009

Plasma volume expansion of more than 1.5 1 and sustainable activation of the hemostatic system that results in a steady rise of the fibrinogen/fibrin turnover are contemporary physiological events during normal pregnancy. In contrast, adverse outcome of pregnancy i.e. pre-eclampsia commonly coincide with hemo concentration and over activation of blood coagulation both of which alter blood rheology. On the basis of 4,985 consecutively recorded singleton pregnancies values range of blood rheological parameters in women with normal and complicated outcome of pregnancy at the time of their delivery were compared. Plasma viscosity (pv) was determined using KSPV 1 Fresenius and RBC aggregation (s…

Erythrocyte Aggregationmedicine.medical_specialtyPhysiologyFibrinogenUmbilical cordGastroenterologyFibrinPregnancyPhysiology (medical)Internal medicinemedicineHumansRetrospective StudiesFetusPregnancyFetal Growth Retardationbiologybusiness.industrySmokingInfant NewbornPregnancy OutcomeHematologyBlood flowInfant Low Birth Weightmedicine.diseaseBlood ViscositySurgeryPregnancy Complicationsmedicine.anatomical_structureHematocritHemorheologybiology.proteinFemaleHemoglobinmedicine.symptomCardiology and Cardiovascular MedicinebusinessWeight gainmedicine.drugClinical hemorheology and microcirculation
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct

Real-time pricing for aggregates energy resources in the Italian energy market

2015

Abstract Over the last decade, the architecture of the energy market has radically changed. In many countries end-users are now able to directly access the market, which has given rise to the question of how they can actively participate in that market. End-users can comprise a critical mass through aggregation that is carried out by a third party – to wit the “loads aggregator.” This paper proposes a new framework for generating feasible real-time price curves for those end-users in a demand-response management process. The underlying algorithm generates output curves as the solution to a constrained optimization problem whose objective function is the aggregator's economic benefit. A case…

OptimizationReal time pricingThird partyMechanical EngineeringEnergy resourcesReal time pricingBuilding and Constructioncomputer.software_genrePollutionIndustrial and Manufacturing EngineeringNews aggregatorMicroeconomicsCritical mass (sociodynamics)Settore ING-IND/33 - Sistemi Elettrici Per L'EnergiaGeneral EnergyCommerceEconomicsEnergy marketElectrical and Electronic EngineeringArchitecturecomputerManagement processLoads aggregationCivil and Structural Engineering
researchProduct